AGT, angiotensinogen, 183

N. diseases: 765; N. variants: 43
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors. 30961500 2020
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Thus, normalizing testosterone and inhibiting renal angiotensin II have a renoprotective effect against DN in HG male rats. 30970225 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE The anti-DN benefit of vitamin D can be enhanced when administrated in combination with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. 30287151 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Angiotensin II, reactive oxygen species, and other factors in the setting of DKD stimulate drastic increases in calcium influx through the TRPC6 channel, causing podocyte hypertrophy and foot process effacement. 31115705 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE The intrarenal renin-angiotensin system, in particular augmentation of angiotensinogen (AGT) in proximal tubular cells (PTC), plays a crucial role in the development of diabetic nephropathy. 30466736 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 GeneticVariation disease BEFREE Our study indicated that the T174M polymorphism in the AGT gene was associated with DN in Asians. 30798724 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE ET-1 and AngII were also significantly decreased in three treatment groups (p < 0.01 vs. the DKD group), especially in the P + A group. 29185789 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE These data indicate that increasing AcSDKP by blocking the ACE N-domain facilitates sodium excretion and ameliorates diabetic kidney disease independent of intrarenal angiotensin II regulation. 30185469 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor. 30190172 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 AlteredExpression disease BEFREE Microvascular complications were graded as follows: neuropathy by clinical assessment, electrophysiology, vibration and cooling detection thresholds, heart rate variability, and corneal confocal microscopy; retinopathy by ultra-wide-field retinal imaging; and DKD by renal hemodynamic function measured by inulin and para-aminohippurate clearance at baseline and after intravenous infusion of angiotensin II. 30275283 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 GeneticVariation disease BEFREE Comprehensive electronic search in Pubmed, Web of Science, EBSCO, Embase, the Cochrane Library and China National Knowledge Infrastructure (CNKI) to find original articles about the association between AGT M235T polymorphism and DN risk published before 27 September 2017. 29775675 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 GeneticVariation disease BEFREE This study is a continuation of our previous research on the association between angiotensinogen (AGT) gene polymorphisms and DN in patients with T2DM. 29514038 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Supporting our previous findings, the modulation and ANGII-mediated crosstalk between ACE2 and ACE in DN progression was more evident in males. 29884907 2018
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g). 28468961 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Although the diabetic milieu per se , hemodynamic changes, oxidative stress and local growth factors such as angiotensin II (AII) are considered to be mediators in the pathogenesis of diabetic nephropathy, the underlying pathways mediating the changes in glomerular endothelial cells (GECs) are not well understood. 27358275 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE It is noteworthy that the efferent glomerular arteriole is 10 - 100 times more sensitive to the vasoconstrictive properties of angiotensin II than the afferent one and this might account for the consequently higher intra-glomerular capillary pressure, which is believed to be the cornerstone of diabetic nephropathy. 28177279 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 GeneticVariation disease BEFREE AGT rs699 and rs4762 missense polymorphisms are not associated with DN in our subset of Slovenian T2DM patients. 28488548 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE The present study has demonstrated, for the first time, that high glucose augments AGT in human RPTCs through HNF-5, which provides a potential therapeutic target for diabetic nephropathy. 29053707 2017
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE The effects of some RAAS gene variants, including angiotensin converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R), on the risk for DN have been studied more extensively, but there has been controversy. 26619914 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney and recognized to be renoprotective by degrading Angiotensin II to Angiotensin (1-7) in diabetic nephropathy. 25791940 2015
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 AlteredExpression disease BEFREE These data suggest that the augmented angiotensinogen mRNA levels in segment 3 and angiotensinogen protein levels in segments 1 and 3 may contribute to the progression of diabetic nephropathy. 24910532 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE Although key signal transduction and gene regulation mechanisms have been identified, especially those related to the effects of hyperglycaemia, transforming growth factor β1 and angiotensin II, progress in functional genomics, high-throughput sequencing technology, epigenetics and systems biology approaches have greatly expanded our knowledge and uncovered new molecular mechanisms and factors involved in DN. 25003613 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE The blockade of angiotensin II (Ang II) is a major therapeutic strategy for diabetic nephropathy. 25148511 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 GeneticVariation disease BEFREE Gene-gene interaction between acetyl-coenzymeA carboxylase beta (ACACβ) gene, which is involved in fatty acid metabolism and angiotensin II receptors (AGTR1) gene, which mediates RAS proteins actions on renal tissue, polymorphism with DN have not been studied earlier. 23081748 2013
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.400 Biomarker disease BEFREE These data suggest the importance of the activated oxidative stress/AGT/RAS axis in the pathogenesis of diabetic nephropathy. 24284398 2013